Scholarlink

<p>In clinical practice, the question “Is breastfeeding allowed?” is often raised when pharmacological treatment is required. However, this approach is misleading. The correct perspective is the following: “The mother is breastfeeding -&#xa0;which medication is appropriate?” With very few exceptions, drugs that are both effective and compatible with breastfeeding can be found for virtually all diseases. Pharmacological properties such as molecular size, lipophilicity, protein binding, pH dependency, and half-life determine drug transfer into breast milk. In practice, the relative infant dose (RID) is a&#xa0;key parameter; values below 10% are generally considered safe. In addition to drug characteristics, the infant’s age, health status, and the duration and route of maternal therapy must be taken into account. While single doses are usually unproblematic, long-term therapies require closer evaluation. Absolute contraindications are rare but include cytotoxic drugs, radionuclides, and radioactive iodine. A&#xa0;structured clinical guideline supports decision-making in everyday practice. Reliable sources such as Embryotox or standard reference texts by Schaefer and Hale are essential. The overall goal is to ensure necessary maternal therapy while preserving breastfeeding.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medikamente in der Stillzeit

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Natalie Groiss,
  • Thomas Zöggeler,
  • Lukas Wisgrill,
  • Gudrun von der Ohe,
  • Daniela Karall

摘要

In clinical practice, the question “Is breastfeeding allowed?” is often raised when pharmacological treatment is required. However, this approach is misleading. The correct perspective is the following: “The mother is breastfeeding - which medication is appropriate?” With very few exceptions, drugs that are both effective and compatible with breastfeeding can be found for virtually all diseases. Pharmacological properties such as molecular size, lipophilicity, protein binding, pH dependency, and half-life determine drug transfer into breast milk. In practice, the relative infant dose (RID) is a key parameter; values below 10% are generally considered safe. In addition to drug characteristics, the infant’s age, health status, and the duration and route of maternal therapy must be taken into account. While single doses are usually unproblematic, long-term therapies require closer evaluation. Absolute contraindications are rare but include cytotoxic drugs, radionuclides, and radioactive iodine. A structured clinical guideline supports decision-making in everyday practice. Reliable sources such as Embryotox or standard reference texts by Schaefer and Hale are essential. The overall goal is to ensure necessary maternal therapy while preserving breastfeeding.